|
Álvarez-Uría A, et al.
|
Invasive Scedosporium and Lomentosora infections in the era of antifungal prophylaxis: A 20-year experience from a single centre in Spain.
|
Mycoses 2020; 63:1195-1202.
|
Breakthrough Fungal Infections
|
|
|
Ananda-Rajah MR, et al.
|
Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. (FREE FULL TEXT)
|
Haematologica 2012; 97:459-463.
|
Breakthrough Fungal Infections
|
|
|
Ashbee HR, et al.
|
Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. (FREE FULL TEXT)
|
J Antimicro Chemo 2014; 69: 1162-1176.
|
Breakthrough Fungal Infections
|
|
|
Breda GL, et al.
|
Breakthrough candidemia after the introduction of broad spectrum antifungal agents: A 5-year retrospective study. (FREE FULL TEXT)
|
Med Mycol 2018; 56:406-415.
|
Breakthrough Fungal Infections
|
|
|
Cattaneo C, et al.
|
Serum posaconazole levels during acute myeloid leukaemia induction therapy: correlations with breakthrough invasive fungal infections.
|
Mycoses 2015; 58:362-367.
|
Breakthrough Fungal Infections
|
|
|
Chae H, et al.
|
Determination of posaconazole concentration with LC-MS/MS in adult patients with hematologic malignancy.
|
Clin Chim Acta 2015; 450:220-226.
|
Breakthrough Fungal Infections
|
|
|
Chan SY, et al.
|
Reasons for voriconazole prophylaxis discontinuation in allogeneic hematopoietic cell transplant recipients: A real-life paradigm.
|
Med Mycol 2020; 58:1029-1036.
|
Breakthrough Fungal Infections
|
|
|
Cornely OA, et al.
|
Defining breakthrough invasive fungal infection-Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology. (FREE FULL TEXT)
|
Mycoses 2019; 62:716-729.
|
Breakthrough Fungal Infections
|
|
|
Donnelly JP, et al.
|
Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. (FREE FULL TEXT)
|
Clin Infect Dis 2020;71(6):1367–76.
|
Breakthrough Fungal Infections
|
|
|
Girmenia C, et al.
|
Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management. (FREE FULL TEXT)
|
Med Mycol 2019; 57:S127-137.
|
Breakthrough Fungal Infections
|
|
|
et al.
Jenks JD, et al.
|
Breakthrough invasive fungal infections: Who is at risk?
|
Mycoses 2020; 63:1021-1032.
|
Aspergillosis in the ICU
Breakthrough Fungal Infections
|
|
|
Lass-Flörl C. et al.
|
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. (FREE FULL TEXT)
|
Antimicrob Agents Chemother 2008;52(10):3637-3641.
|
Breakthrough Fungal Infections
Mode of Action
|
|
|
Lerolle N, et al.
|
Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study. (FREE FULL TEXT)
|
Clin Microbiol Infect 2014; 20:O952-O959.
|
Breakthrough Fungal Infections
|
|
|
Lewis RE, et al.
|
Voriconazole pre-exposure selects for breakthrough mucormycosis in a mixed model of Aspergillus fumigatus-Rhizopus oryzae pulmonary infection. (FREE FULL TEXT)
|
Virulence 2011; 2:348-355.
|
Breakthrough Fungal Infections
|
|
|
Lionakis MS, et al.
|
Breakthrough Invasive Mold Infections in the Hematology Patient: Current Concepts and Future Directions. (FREE FULL TEXT)
|
Clin Infect Dis 2018; 67:1621-1630.
|
Breakthrough Fungal Infections
|
|
|
Maschmeyer G & Patterson TF
|
Our 2014 approach to breakthrough invasive fungal infections.
|
Mycoses 2014; 57:645-651.
|
Breakthrough Fungal Infections
|
|
|
Oh J, et al.
|
Antifungal prophylaxis with posaconazole tablet and oral suspension in patients with haematologic malignancy: Therapeutic drug monitoring, efficacy and risk factors for the suboptimal level.
|
Mycoses 2020; 63:89-94.
|
Breakthrough Fungal Infections
|
|
|
Patterson TF, et al.
|
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. (FREE FULL TEXT)
|
Clin Infect Dis 2016; 63:e1-60.
|
Breakthrough Fungal Infections
|
|
|
Tissot F, et al.
|
ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. (FREE FULL TEXT)
|
Haematologica 2017; 102:433-444.
|
Breakthrough Fungal Infections
|
|
|
Trifilio S, et al.
|
Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. (FREE FULL TEXT)
|
Bone Marrow Transplant 2007; 40:451–6.
|
Breakthrough Fungal Infections
|
|
|
Tverdek FP, et al.
|
Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses. (FREE FULL TEXT)
|
Antimicrob Agents Chemother 2017; 61 e00188-17.
|
Breakthrough Fungal Infections
|
|
|
Vahedi Shahandashti R & Lass-Flörl C
|
Antifungal resistance in Aspergillus terreus: A current scenario.
|
Fungal Genet Biol 2019; 131:103247.
|
Aspergillosis in the ICU
Breakthrough Fungal Infections
|
|
|
van der Linden JWM, et al.
|
Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. (FREE FULL TEXT)
|
Clin Infect Dis 2013; 57:513-520.
|
Breakthrough Fungal Infections
|
|
|
Walsh TJ, et al.
|
Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. (FREE FULL TEXT)
|
N Engl J Med 1999; 340:764–71.
|
Breakthrough Fungal Infections
Mode of Action
Nephrotoxicity
|
|
|
et al.
Walsh TJ, et al.
|
Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. (FREE FULL TEXT)
|
N Engl J Med 2002; 346:225-34.
|
Aspergillosis in the ICU
Breakthrough Fungal Infections
Nephrotoxicity
|
|
|
Walsh TJ, et al.
|
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. (FREE FULL TEXT)
|
N Engl J Med 2004; 351:1391-1402.
|
Breakthrough Fungal Infections
Nephrotoxicity
|
|
|
Wasylyshyn A, et al.
|
Breakthrough Invasive Fungal Infections in Patients with Acute Myeloid Leukemia.
|
Mycopathologica 2020; 185:299-306.
|
Breakthrough Fungal Infections
|
|
|
Yoshida M, et al.
|
A real-world prospective observational study on the efficacy and safety of liposomal amphotericin B in 426 patients with persistent neutropenia and fever. (FREE FULL TEXT)
|
J Infect Chemother 2021; 27:P277-283.
|
Breakthrough Fungal Infections
|
|
|
Alvarez-Lerma F, et al.
|
Impact of the administration of liposomal amphotericin B in patients with renal function impairment at initiation of treatment.
|
J Chemother 2010; 22:285-287.
|
Intensive Care
|
|
|
Chowdhary A, et al.
|
Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. (FREE FULL TEXT)
|
PLoS Pathog 2017; 13:e1006290.
|
Intensive Care
|
|
|
Crum-Cianflone NF
|
Invasive Aspergillosis Associated With Severe Influenza Infections. (FREE FULL TEXT)
|
Open Forum Infect Dis 2016; 3:ofw171.
|
Intensive Care
Intro nurses
Mode of Action
|
|
|
Ericsson J, et al.
|
Candidaemia in Sweden: a nationwide prospective observational survey. (FREE FULL TEXT)
|
Clin Microbiol Infect 2013; 19:E218-E221.
|
Intensive Care
|
|
|
Felton T, et al.
|
Tissue penetration of antifungal agents. (FREE FULL TEXT)
|
Clin Microbiol Rev 2014; 27:68-88.
|
Intensive Care
|
|
|
Groth CM & Dodds-Ashley ES
|
Fungal Infections in the ICU. (FREE FULL TEXT)
|
In: Infection Critical Care. CCSAP 2016, 1-23.
|
Intensive Care
Mode of Action
|
|
|
Iwaki T, et al.
|
Multiple functions of ergosterol in the fission yeast Schizosaccharomyces pombe. (FREE FULL TEXT)
|
Microbiology 2008; 154:830-841.
|
Intensive Care
|
|
|
Kollef M, et al.
|
Septic shock attributed to Candida infection: importance of empiric therapy and source control. (FREE FULL TEXT)
|
Clin Infect Dis 2012; 54:1739-1746.
|
Intensive Care
Intro nurses
|
|
|
Kuse ER, et al.
|
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial.
|
Lancet 2007; 369:1519-1527.
|
Intensive Care
|
|
|
Lewis RE
|
Pharmacodynamic implications for use of antifungal agents.
|
Curr Opin Pharmacol 2007; 7:491-497.
|
Intensive Care
|
|
|
et al.
Muskett H, et al.
|
Risk factors for invasive fungal disease in critically ill adult patients: a systematic review. (FREE FULL TEXT)
|
Crit Care 2011; 15:R287.
|
Intensive Care
Intro nurses
Mode of Action
|
|
|
Paramythiotou E, et al.
|
Invasive fungal infections in the ICU: how to approach, how to treat. (FREE FULL TEXT)
|
Molecules 2014; 19:1085-1119.
|
Intensive Care
Mode of Action
|
|
|
Perlin DS, et al.
|
The global problem of antifungal resistance: prevalence, mechanisms, and management. (FREE FULL TEXT)
|
Lancet Infect Dis 2017; 17:e383-392.
|
Intensive Care
|
|
|
Sanglard D
|
Emerging Threats in Antifungal-Resistant Fungal Pathogens. (FREE FULL TEXT)
|
Front Med (Lausanne) 2016; 3:1-10.
|
Intensive Care
|
|
|
et al.
Tumbarello M, et al.
|
Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. (FREE FULL TEXT)
|
J Clin Microbiol 2007; 45:1843-1850.
|
Intensive Care
Intro nurses
|
|
|
Vincent J-L, et al.
|
International study of the prevalence and outcomes of infection in intensive care units. (FREE FULL TEXT)
|
JAMA 2009; 302:2323-2329.
|
Intensive Care
|
|
|
Walker L, et al.
|
The Viscoelastic Properties of the Fungal Cell Wall Allow Traffic of AmBisome as Intact Liposome Vesicles. (FREE FULL TEXT)
|
MBio 2018; 9:e02383-17.
|
Intensive Care
Mode of Action
|
|
|
De Pauw B, et al.
|
Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. (FREE FULL TEXT)
|
Clin Infect Dis 2008; 46:1813–21.
|
Influenza and Aspergillus
|
|
|
et al.
Schauwvlieghe A, et al.
|
Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study.
|
Lancet Respir Med 2018; 6(10):782-792.
|
Aspergillosis in the ICU
Influenza and Aspergillus
|
|
|
Dupont D, et al.
|
Pulmonary aspergillosis in critically ill patients with Coronavirus Disease 2019 (COVID-19). (FREE FULL TEXT)
|
Med Mycol 2021; 59(1):110-114. doi: 10.1093/mmy/myaa078.
|
Covid and Aspergillus
|
|
|
Fekkar A. et al.
|
Occurrence of Invasive Pulmonary Fungal Infections in Patients with Severe COVID-19 Admitted to the ICU. (FREE FULL TEXT)
|
Am J Respir Critical Care Med 2021; 203(3):307-317. doi: 10.1164/rccm.202009-3400OC.
|
Covid and Aspergillus
|
|
|
Gouzien L, et al.
|
Invasive Aspergillosis Associated with severe COVID-19: A Word of Caution. (FREE FULL TEXT)
|
Infect Dis Now 2021. doi: 10.1016/j.idnow.2020.12.008. Online ahead of print.
|
Covid and Aspergillus
|
|
|
Koehler P, et al.
|
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. (FREE FULL TEXT)
|
Lancet Infect Dis 2020;S1473-3099(20)30847-1. doi: 10.1016/S1473-3099(20)30847-1. Online ahead of print.
|
Covid and Aspergillus
|
|
|
Marr KA, et al.
|
Aspergillosis Complicating Severe Coronavirus Disease. (FREE FULL TEXT)
|
Emerg Infect Dis 2021;27(1):18-25. doi: 10.3201/eid2701.202896.
|
Covid and Aspergillus
|
|
|
Meijer EFJ, et al.
|
COVID-19-associated pulmonary aspergillosis: a prospective single-center dual case series. (FREE FULL TEXT)
|
Mycoses 2021; 64(4):457-464. doi: 10.1111/myc.13254.
|
Covid and Aspergillus
|
|
|
Salmanton-García J, et al.
|
COVID-19-Associated Pulmonary Aspergillosis, March-August 2020. (FREE FULL TEXT)
|
Emerg Infect Dis 2021; 27(4). doi: 10.3201/eid2704.204895. Online ahead of print.
|
Covid and Aspergillus
|
|
|
van Grootveld R, et al.
|
Systematic screening for COVID-19 associated invasive aspergillosis in ICU patients by culture and PCR on tracheal aspirate. (FREE FULL TEXT)
|
Mycoses 2021; doi: 10.1111/myc.13259. Online ahead of print.
|
Covid and Aspergillus
|
|
|
Waizel-Haiat S, et al.
|
A Case of Fatal Rhino-Orbital Mucormycosis Associated With New Onset Diabetic Ketoacidosis and COVID-19. (FREE FULL TEXT)
|
Cureus 2021; 13(2):e13163. doi: 10.7759/cureus.13163.
|
Covid and Aspergillus
|
|
|
Warris A & Schwartz I
|
Editorial MMCR special issue ‘Covid-19 associated pulmonary aspergillosis’. (FREE FULL TEXT)
|
Med Mycol Case Rep 2021;31:1.
|
Covid and Aspergillus
|
|
|
Alvarez-Lerma F, et al.
|
Use of liposomal amphotericin B in critically ill patients: a retrospective, multicenter, clinical study.
|
J Chemother 2009; 21:330‒7.
|
Nephrotoxicity
|
|
|
Cornely OA, et al.
|
Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). (FREE FULL TEXT)
|
Clin Infect Dis 2007; 44:1289–97.
|
Nephrotoxicity
|
|
|
Deray G
|
Amphotericin B nephrotoxicity. (FREE FULL TEXT)
|
J Antimicrob Chemother 2002; 49 (S1):S37‒41.
|
Nephrotoxicity
|
|
|
Falci DR, et al.
|
Comparison of nephrotoxicity associated to different lipid formulations of amphotericin B: a real-life study.
|
Mycoses 2015: 58;104‒12.
|
Nephrotoxicity
|
|
|
KDIGO 2012
|
Clinical Practice Guidelines for the Evaluation and Management of Chronic Kidney Disease. (FREE FULL TEXT)
|
Accessed March 2021
|
Nephrotoxicity
|
|
|
Laniado-Laborín R, et al.
|
Amphotericin B: side effects and toxicity. (FREE FULL TEXT)
|
Rev Iberoam Micol 2009; 26:223‒7.
|
Nephrotoxicity
|
|
|
Loo AS, et al.
|
Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B.
|
Expert Opin Drug Saf 2013; 12(6):881–95.
|
Nephrotoxicity
|
|
|
Prentice HG, et al.
|
A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. (FREE FULL TEXT)
|
Br J Haematol. 1997; 98:711–8.
|
Nephrotoxicity
|
|
|
The Renal Association
|
CKD Stages. (FREE FULL TEXT)
|
Accessed March 2021
|
Nephrotoxicity
|
|
|
Adler-Moore JP, et al.
|
Comparison between liposomal formulations of amphotericin B. (FREE FULL TEXT)
|
Med Mycol 2016; 54(3):223-231.
|
Mode of Action
|
|
|
Alexander BD, et al.
|
Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. (FREE FULL TEXT)
|
Clin Infect Dis 2013; 56(12):1724-1732.
|
Mode of Action
|
|
|
Arendrup MC
|
Update on antifungal resistance in Aspergillus and Candida. (FREE FULL TEXT)
|
Clin Microbiol Infect 2014: 20(Suppl 6):42-48.
|
Mode of Action
|
|
|
Farmakiotis D & Kontoyiannis DP
|
Mucormycoses.
|
Infect Dis Clin North Am 2016; 30(1):143-163.
|
Mode of Action
|
|
|
Fernández-Garcia R, et al.
|
Unmet clinical needs in the treatment of systemic fungal infections: The role of amphotericin B and drug targeting.
|
Int J Pharm 2017; 525(1):139-148.
|
Mode of Action
|
|
|
Fridkin SK
|
The changing face of fungal infections in health care settings. (FREE FULL TEXT)
|
Clin Infect Dis. 2005; 41(10):1455-1460.
|
Mode of Action
|
|
|
Klepser M
|
The value of amphotericin B in the treatment of invasive fungal infections.
|
J Crit Care 2011; 225:e1-10.
|
Mode of Action
|
|
|
Kontoyiannis DP, et al.
|
Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. (FREE FULL TEXT)
|
Clin Infect Dis 2010; 50(8):1091-1100.
|
Mode of Action
|
|
|
Lamoth F & Calandra T
|
Early diagnosis of invasive mould infections and disease. (FREE FULL TEXT)
|
J Antimicrob Chemother 2017; 72(Suppl 1):i19-i28.
|
Mode of Action
|
|
|
Lamoth F, et al.
|
Changing Epidemiology of Invasive Mold Infections in Patients Receiving Azole Prophylaxis. (FREE FULL TEXT)
|
Clin Infect Dis 2017; 64(11):1619-1621.
|
Mode of Action
|
|
|
Mesa-Arango AC, et al.
|
The production of reactive oxygen species is a universal action mechanism of Amphotericin B against pathogenic yeasts and contributes to the fungicidal effect of this drug. (FREE FULL TEXT)
|
Antimicrob Agents Chemother 2014; 58(11):6627-6638.
|
Mode of Action
|
|
|
Mesa-Arango AC, et al.
|
It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug. (FREE FULL TEXT)
|
Front Microbiol 2012; 3(286):1-10.
|
Mode of Action
|
|
|
Morace G & Borghi E
|
Fungal infections in ICU patients: epidemiology and the role of diagnostics. (FREE FULL TEXT)
|
Minerva Anestesiol 2010; 76(11):950-956.
|
Mode of Action
|
|
|
Pagano L, et al
|
The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study.
|
Haematologica 2006; 91:1068-1075.
|
Mode of Action
|
|
|
Perlin DS
|
Mechanisms of echinocandin antifungal drug resistance. (FREE FULL TEXT)
|
Ann N Y Acad Sci 2015; 1354:1-11.
|
Mode of Action
|
|
|
Richardson M & Lass-Flörl C
|
Changing epidemiology of systemic fungal infections. (FREE FULL TEXT)
|
Clin Microbiol Infect 2008; 14(Suppl 4):5-24.
|
Mode of Action
|
|
|
Shields RK, et al.
|
Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure. (FREE FULL TEXT)
|
Antimicrob Agents Chemother 2013; 57(8):3528-3535.
|
Mode of Action
|
|
|
Skiada A, et al.
|
Challenges in the diagnosis and treatment of mucormycosis. (FREE FULL TEXT)
|
Med Mycol 2018; 56(Suppl 1):93-101.
|
Mode of Action
|
|
|
Stone NR, et al.
|
Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions. (FREE FULL TEXT)
|
Drugs 2016; 76(4):485-500.
|
Mode of Action
|
|
|
Ullmann A, et al.
|
Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. (FREE FULL TEXT)
|
Clin Infect Dis 2006; 43:e29-38.
|
Mode of Action
|
|
|
Vallejo C, et al.
|
Treatment of invasive fungal infections in high-risk haematological patients: what have we learnt in the past 10 years? (FREE FULL TEXT)
|
Rev Esp Quimioter 2013; 26(4):378-386.
|
Mode of Action
|
|
|
van der Linden JWM, et al.
|
Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. (FREE FULL TEXT)
|
Emerg Infect Dis 2011; 17(10):1846-1854.
|
Mode of Action
|
|
|
Wingard JR, et al.
|
A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. (FREE FULL TEXT)
|
Clin Infect Dis 2000; 31:1155-1163.
|
Mode of Action
|
|
|
Wisplinghoff H, et al.
|
Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. (FREE FULL TEXT)
|
Clin Infect Dis 2004; 39(3):309-317.
|
Mode of Action
|
|
|
Wong-Beringer A & Kriengkauykiat J
|
Systemic antifungal therapy: new options, new challenges.
|
Pharmacotherapy 2003; 23(11):1441-1462.
|
Mode of Action
|
|
|
Armstrong-James D et al.
|
A neglected epidemic: fungal infections in HIV/AIDS.
|
Trends Microbiol 2014; 22(3):120-127
|
Intro nurses
|
|
|
Cram Flashcards
|
Beginning Fungi (FREE FULL TEXT)
|
Accessed June 2022
|
Intro nurses
|
|
|
Kosmidis C & Denning DW
|
Republished: The clinical spectrum of pulmonary aspergillosis
|
Postgrad Med J 2015; 91(1077):403-410
|
Intro nurses
|
|
|
Nammex
|
Redefining Medicinal Mushrooms (FREE FULL TEXT)
|
Accessed June 2022
|
Intro nurses
|
|
|
Negroni R
|
Cryptococcosis (FREE FULL TEXT)
|
Clin Dermatol 2012; 30(6):599-609
|
Intro nurses
|
|
|
Nett JE & Andes DR
|
Antifungal Agents: Spectrum of Activity, Pharmacology, and Clinical Indications
|
Infect Dis Clin North Am 2016; 30(1):51-83
|
Intro nurses
|
|
|
Paramythiotou E et al
|
Invasive fungal infections in the ICU: how to approach, how to treat (FREE FULL TEXT)
|
Molecules 2014; 19(1):1085-1119
|
Intro nurses
|
|
|
The Fungal Infection Trust
|
Aspergillosis (FREE FULL TEXT)
|
Accessed June 2022
|
Intro nurses
|
|
|
Bassetti M et al
|
How to manage aspergillosis in non-neutropenic intensive care unit patients (FREE FULL TEXT)
|
Crit Care 2014; 18(4):458
|
Aspergillosis in the ICU
|
|
|
Cornely OA et al
|
Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease
|
Mycoses 2011; 54:e449-e455
|
Aspergillosis in the ICU
|
|
|
Dimopoulos G et al
|
Invasive aspergillosis in the intensive care unit
|
Review Ann N Y Acad Sci 2012;1272:31-39
|
Aspergillosis in the ICU
|
|
|
Garnacho-Montero J et al
|
Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome (FREE FULL TEXT)
|
Crit Care 2005; 9(3):R191-R199
|
Aspergillosis in the ICU
|
|
|
Khasawneh F et al
|
Isolation of Aspergillus in critically ill patients: a potential marker of poor outcome
|
J Crit Care 2006; 21(4):322-327
|
Aspergillosis in the ICU
|
|
|
Lewis RE
|
Current concepts in antifungal pharmacology (FREE FULL TEXT)
|
Mayo Clin Proc 2011; 86(8):805-817
|
Aspergillosis in the ICU
|
|
|
|
Invasive aspergillosis in critically ill patients without malignancy (FREE FULL TEXT)
|
Am J Respir Crit Care Med 2004; 170(6):621-625
|
Aspergillosis in the ICU
|
|
|
Meersseman W et al
|
Invasive aspergillosis in the intensive care unit (FREE FULL TEXT)
|
Clin Infect Dis 2007; 45:205-216
|
Aspergillosis in the ICU
|
|
|
Nivoix Y et al
|
Factors associated with overall and attributable mortality in invasive aspergillosis (FREE FULL TEXT)
|
Clin Infect Dis 2008; 47:1176-1184
|
Aspergillosis in the ICU
|
|
|
Peyton LR et al
|
Triazole antifungals: a review
|
Drugs Today 2015; 51:705-718
|
Aspergillosis in the ICU
Breakthrough Fungal Infections
|
|
|
Sucher AJ et al
|
Echinocandins: the newest class of antifungals
|
Ann Pharmacother. 2009; 43:1647-57
|
Aspergillosis in the ICU
Breakthrough Fungal Infections
|
|
|
Taccone FS et al
|
Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes (FREE FULL TEXT)
|
Crit Care 2015; 19(1):7
|
Aspergillosis in the ICU
|
|
|
Vanderbeke L et al
|
Invasive pulmonary aspergillosis complicating severe influenza: epidemiology, diagnosis and treatment
|
Curr Opin Infect Dis 2018; 31:471-480
|
Aspergillosis in the ICU
|
|
|
Vandewoude KH et al
|
Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients (FREE FULL TEXT)
|
Crit Care 2006; 10(1):R31
|
Aspergillosis in the ICU
|
|
|
Vandewoude KH et al
|
Invasive aspergillosis in critically ill patients: attributable mortality and excesses in length of ICU stay and ventilator dependence
|
J Hosp Infect 2004; 56(4):269-276
|
Aspergillosis in the ICU
|
|
|
Andes D et al
|
Drug-Drug Interaction Associated with Mold-Active Triazoles among Hospitalized Patients (FREE FULL TEXT)
|
Antimicrob Agent Chemother. 2016; 60(6):3398-406
|
Breakthrough Fungal Infections
|
|
|
Buajordet I et al
|
Fatal adverse drug events: the paradox of drug treatment (FREE FULL TEXT)
|
J Intern Med. 2001; 250:327-41
|
Breakthrough Fungal Infections
|
|
|
Cousin L et al
|
Dosing guidelines for fluconazole in patients with renal failure (FREE FULL TEXT)
|
Nephrol Dial Transplant. 2003; 18:2227-31
|
Breakthrough Fungal Infections
|
|
|
Koeck JA et al
|
Clinically Relevant Interactions with Anti-Infectives on Intensive Care Units-A Multicenter Delphi Study (FREE FULL TEXT)
|
Antibiotics 2021; 10:1330
|
Breakthrough Fungal Infections
|
|
|
Sandherr M & Maschmeyer G
|
Pharmacology and metabolism of voriconazole and Posaconazole in the treatment of invasive aspergillosis: review of the literature (FULL FREE TEXT)
|
Eur J Med Res. 2011; 16(4):139-44
|
Breakthrough Fungal Infections
|
|
|
Scripture CD et al
|
Drug interactions in cancer therapy (FREE FULL TEXT)
|
Nat Rev Cancer. 2006; 6:546-58
|
Breakthrough Fungal Infections
|
|
|
Teo YL et al
|
Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations (FREE FULL TEXT)
|
Br J Clin Pharmacol. 2015; 79:241-53
|
Breakthrough Fungal Infections
|
|
|
van Leeuwen RWF et al
|
Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs (FREE FULL TEXT)
|
Br J Cancer. 2013; 108:1071-83
|
Breakthrough Fungal Infections
|
|
|
Petrikkos G et al
|
Epidemiology and clinical manifestations of mucormycosis (FREE FULL TEXT)
|
Clin Infect Dis 2012; 54 Suppl 1:S23-34
|
Intensive Care
|
|
|
Brunet K & Rammaert B
|
Mucormycosis treatment: Recommendations, latest advances, and perspectives
|
J Mycol Med 2020; 30(3):101007
|
Mucormycosis
|
|
|
Corzo-León DE et al
|
Diabetes mellitus as the major risk factor for mucormycosis in Mexico: Epidemiology, diagnosis, and outcomes of reported cases (FREE FULL TEXT)
|
Med Mycol 2018; 56(1):29-43
|
Mucormycosis
|
|
|
Cornely OA et al
|
Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium (FREE FULL TEXT)
|
Lancet Infect Dis 2019; 19(12):e405-e421
|
Mucormycosis
|
|
|
Khatri A et al
|
is after Coronavirus disease 2019 infection in a heart transplant recipient – Case report and review of literature (FREE FULL TEXT)
|
J Mycol Med 2021; 31(2):101125
|
Mucormycosis
|
|
|
Lass-Flörl C & Cuenca-Estrella M
|
Changes in the epidemiological landscape of invasive mould infections and disease (FREE FULL TEXT)
|
J Antimicrob Chemother 2017; 72(suppl_1):i5-i11
|
Mucormycosis
|
|
|
Messer SA et al
|
In vitro activity of isavuconazole versus opportunistic filamentous fungal pathogens from the SENTRY Antifungal Surveillance Program, 2017-2018
|
Diagn Microbiol Infect Dis 2020; 97(1):115007
|
Mucormycosis
|
|
|
Moorthy A et al
|
SARS-CoV-2, Uncontrolled Diabetes and Corticosteroids-An Unholy Trinity in Invasive Fungal Infections of the Maxillofacial Region? A Retrospective, Multi-centric Analysis (FREE FULL TEXT)
|
J Maxillofac Oral Surg 2021; 20(3):1-8
|
Mucormycosis
|
|
|
Nett JE & Andes DR
|
Antifungal Agents: Spectrum of Activity, Pharmacology, and Clinical Indications
|
Review Infect Dis Clin North Am 2016; 30(1):51-83
|
Mucormycosis
|
|
|
Reid G et al
|
Mucormycosis
|
Review Semin Respir Crit Care Med 2020; 41(1):99-114
|
Mucormycosis
|
|
|
Skiada A et al
|
Challenges in the diagnosis and treatment of mucormycosis (FREE FULL TEXT)
|
Review Med Mycol 2018; 56(suppl_1):93-101
|
Mucormycosis
|
|
|
Song G et al
|
Fungal Co-infections Associated with Global COVID-19 Pandemic: A Clinical and Diagnostic Perspective from China (FREE FULL TEXT)
|
Mycopathologia 2020; 185(4):599-606
|
Mucormycosis
|
|
|
Szarpak L et al
|
Mucormycosis-A serious threat in the COVID-19 pandemic? (FREE FULL TEXT)
|
J Infect 2021; 83(2):237-279
|
Mucormycosis
|
|
